Health Education vs Meditation in Irreversible Age-Related Vision Loss Patients and Their Caregivers (NCT03166072) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Health Education vs Meditation in Irreversible Age-Related Vision Loss Patients and Their Caregivers
Canada150 participantsStarted 2026-04-20
Plain-language summary
Investigators aim to assess the feasibility of delivering two augmentation interventions, Meditation and a Health Enhancement Program, for potentially enhancing the quality of life and mental health of Irreversible Age-Related Vision Loss (IARVL) patients and/or their caregivers.
Who can participate
Age range18 Years – 85 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients with irreversible age-related vision loss (IARVL) and have ongoing significant disability and/or their caregivers who agree to consent.
* IARVL patients between age 60 to 85 years or caregivers between 18 to 85 years.
* Deemed competent to provide individual consent to participate.
* Speak and understand English without requirement for interpretation or assistance.
* Have no significant self-reported or physician diagnosed mental health disorder other than depressive and/or anxiety symptoms.
* Have either a minimum of CES-D 20-item scale score of 16 OR a minimum of 8 on the Hospital Anxiety Scale (HADS-A) 7-item sub-scale.
* Have sufficient hearing to be able to follow verbal instructions
* Ability to sit independently without physical discomfort for 30 minutes.
* Willing and able to attend, via Microsoft TEAMS software, the four initial training sessions of MEDITATION or HEP and at least 6 follow-up sessions.
* Willing to dedicate 33 minutes per day to their assigned home practice.
Exclusion Criteria:
* Inability to provide informed consent.
* Dementia as defined by MoCA \< 21.
* Have significant suicidal ideation as per self-report (CES-D = 3 on item question 14 and/or 15).
* Have severe depression CES-D ≥ 24.
* Participating in other similar studies.
* Have a lifetime diagnosis of self-reported other mental disorders, including bipolar I or II disorder, primary psychotic disorder (schizophrenia, schizoaffective disorder, schizophreniform d…
What they're measuring
1
Participants screened
Timeframe: Through study completion, an average of 1 year
2
Participants enrolled
Timeframe: Through study completion, an average of 1 year
3
Retention rate
Timeframe: Up to 12 weeks.
4
Adherence rate
Timeframe: Up to 12 weeks
5
Assessment rating and duration
Timeframe: Up to 12 weeks
6
Intervention cost
Timeframe: Up to 12 weeks
7
Data quality
Timeframe: Up to 12 weeks
Trial details
NCT IDNCT03166072
SponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's